Skip to content

Study · In vitro (cells) · mouse · 1996

1 result

The antiproliferative activity of the tetrapeptide Acetyl-N-SerAspLysPro, an inhibitor of haematopoietic stem cell proliferation, is not mediated by a thymosin beta 4-like effect on actin assembly.

Cheviron N, Grillon C, Carlier MF, Wdzieczak-Bakala J

Cell proliferation1 Aug 1996Cited by 3 (Europe PMC)

PMID8918557 (opens in a new tab)DOI10.1111/j.1365-2184.1996.tb00986.x (opens in a new tab)PepBankPUB-08918557
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In murine primitive bone marrow cells in vitro, thymosin beta‑4, like AcSDKP, inhibited entry into the cell cycle.

    In plain wordsIn mouse bone marrow cells in the lab, thymosin beta‑4 slowed cells from starting to divide, like the tetrapeptide AcSDKP.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseEntry of primitive bone marrow cells into cell cycle
    Study

    mousen: not reported in source

    murine primitive bone marrow cells
    Comparator
    AcSDKP
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    Dose not stated · in vitroAs given in this study (mouse).

    Source sentences

    Summary
    The results revealed that T beta 4, like AcSDKP, exerts an inhibitory effect on the entry of murine primitive bone marrow cells into cell cycle in vitro.
    1 context sentence
    Summary · context
    The effect of T beta 4 on the proliferation of haematopoietic cells was compared to that of AcSDKP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.